Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2017-12-06, 11:14:19 | version 1.38.0
| industry From granules to foam Author: Prof. Dr Dr Stefan Schermer, Germany Literature In 1997 curasan launched its first β-TCP based bone regeneration material in granule form CERASORB®. Primary discussed very controversial as not compa- rable to the golden standard iliac crest spongiosa, the development of the biomimetic bone regener- ating materials didn’t stop, at least due to require- ments of health politics and patients’ sensitivity.1 CERASORB® M, significantly closer to natural bone structure was a logical improvement of CERASORB® and ended up in CERASORB® Foam, where the β-TCP granules are imbedded in a collagen foam matrix, due to its flexibility enhancing the indication of β-TCP based bone regeneration materials considerably. For more than a decade (16 years), the author at- tended the development of these modern augmen- tation materials, collecting clinical experience from hundreds of patients. In the following, some exem- plary cases are shown, demonstrating the vast range of CERASORB® products. A patient came to the hospital with unclear dis- comfort in the right mandibular region. Radiologically (Fig. 1), a retained and displaced wisdom tooth with clear and impressive translucency in area 46 and 47 dominated. Block and damage of the inferior alveolar nerve was probable, as well as devitalisation of the two molars. Clinically, a prominent swelling in area 46 and 47 could be seen and a perforation of the soft tissue over the erupting wisdom tooth. After preparation of a soft-tissue flap (Fig. 2) and the sparing removal of the wisdom tooth, the cyst was carefully extirpated. The alveolar nerve could be saved and the enormous defect was filled with CERASORB® granules (Fig. 3). The final wound closure was done by readapting the soft-tissue flap and a sealed off suture. The vitality of the molars was kept, as well as the sensitivity of the inferior alveolar nerve. After nine months, a control panoramic scan was made and a sufficient bony con- solidation with only a few residual CERASORB® gran- ules was noticed (Fig. 4). Case 1: CERASORB® Case 2: CERASORB® M The case documented in 2000 shows the use of the original rounded form of CERASORB®. The second case from 2005 documents the further development and improvement of CERASORB® into 28 implants 3 2017